Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.

Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.

Typhoid fever causes more than 21 million cases of disease and 200,000 deaths yearly worldwide, with more than 90% of the disease burden being reported from Asia. Epidemiological data show high disease incidence in young children and suggest that immunization programs should target children below tw...

Full description

Bibliographic Details
Main Authors: Pierre van Damme, Froukje Kafeja, Alessandra Anemona, Venere Basile, Anne Katrin Hilbert, Ilse De Coster, Simona Rondini, Francesca Micoli, Rana M Qasim Khan, Elisa Marchetti, Vito Di Cioccio, Allan Saul, Laura B Martin, Audino Podda
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3184126?pdf=render

Internet

http://europepmc.org/articles/PMC3184126?pdf=render

Similar Items